Inhibitors of protein arginine deiminases and their efficacy in animal models of multiple sclerosis
作者:Amit Sarswat、Ewa Wasilewski、Sai K. Chakka、Angelica M. Bello、Andrew V. Caprariello、Chithra M. Muthuramu、Peter K. Stys、Shannon E. Dunn、Lakshmi P. Kotra
DOI:10.1016/j.bmc.2017.03.006
日期:2017.5
inflammatory and neurodegenerative diseases including multiple sclerosis (MS). Following the discovery of an in silico hit containing hydantoin and a piperidine moiety, we hypothesized that a 2-carbon linker on the hydantoin would be necessary for a 5-membered heterocycle for optimal PAD inhibitory activity. We designed thirteen compounds as potential inhibitors of PAD2 and PAD4 enzymes-two important PAD enzymes
精氨酸脱亚氨酶(PAD)与多种炎症和神经退行性疾病有关,包括多发性硬化症(MS)。在发现含有乙内酰脲和哌啶部分的计算机模拟药物后,我们假设乙内酰脲上的2碳连接基对于5元杂环具有最佳的PAD抑制活性是必要的。我们设计了13种化合物作为PAD2和PAD4酶的潜在抑制剂,这是MS中涉及的两种重要的PAD酶。两种化合物,一种具有咪唑部分(22),另一种具有四唑部分(24),在体外和MS的EAE小鼠模型中均显示出对PAD同工酶的良好抑制作用。进一步的实验表明,化合物22是PAD2和PAD4的非共价抑制剂,